Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15640894 | 0.81 | PDE10A (0.47) | ALDH1A1L3MBTL1TDP1KMT2ALMNA | |
| SCHEMBL21091020 | 0.80 | PDE10A (0.55) | ALDH1A1TDP1KMT2APDE10AGLA | |
| SCHEMBL5536800 | 0.78 | PDE10A (0.53) | ALDH1A1TDP1KMT2APDE10AGLA | |
| SCHEMBL829862 | 0.78 | PDE10A (0.53) | ALDH1A1L3MBTL1TDP1KMT2AMAPT | |
| SCHEMBL28648764 | 0.77 | PDE10A (0.51) | ALDH1A1KMT2AMAPTPDE10AGLA | |
| SCHEMBL2048608 | 0.77 | HTR2B (0.57) | ALDH1A1L3MBTL1KMT2APDE10ACYP19A1 | |
| SCHEMBL27287019 | 0.77 | CYP3A4 (0.54) | ALDH1A1L3MBTL1KMT2AMAPTPDE10A | |
| SCHEMBL2096012 | 0.77 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1TDP1KMT2ALMNA | |
| SCHEMBL21116004 | 0.77 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1TDP1KMT2ALMNA | |
| SCHEMBL18015824 | 0.77 | ALDH1A1 (0.73) | ALDH1A1L3MBTL1TDP1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171427-A1 | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-19 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-102516239-A | Aromatic thiazole compounds, analogues thereof, uses thereof and preparation methods thereof | UNIV EAST CHINA NORMAL | 2012-06-27 | — | — | CN | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | ALDH1A1 355/4885L3MBTL1 1931/4885TDP1 4666/4885 |
| US-20140171427-A1 | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels | KCNJ2, TRPV1, KCNJ1 | ALDH1A1 1614/4885L3MBTL1 4783/4885TDP1 3870/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | ALDH1A1 412/4885L3MBTL1 2575/4885TDP1 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.